Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Nakamura, Y.
Sano, K.
Fukuda, M.
Takatani, H.
Nagashima, S.
Kinoshita, A.
Fukuda, M.
Soda, H.
Oka, M.
Kohno, S.
机构：
[1] Goto Cent Hosp, Goto, Japan
[2] Meiji Pharmaceut Univ, Tokyo, Japan
[3] Nagasaki Thorac Oncol Grp, Nagasaki, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：81S / 81S
页数：1
相关论文
共 50 条
  • [21] GEFITINIB in advanced non-small cell lung cancer (NSCLC) in expanded access programme: A single center experience
    Kowalczyk, A.
    Szutowicz-Zielinska, E.
    Dziadziuszko, R.
    Badzio, A.
    Madrzak, J.
    Kukowska, A.
    Siemiatkowska, A.
    Limon, J.
    Jassem, J.
    LUNG CANCER, 2006, 52 : S36 - S36
  • [22] Survival predictors in advanced non-small cell lung cancer (NSCLC) patients with clinically proven sensitivity to gefitinib
    Lee, Y.
    Yun, T.
    Han, J.
    Kim, H.
    Lee, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] PRELIMINARY RESULTS OF ANTITUMOR ACTIVITY OF GEFITINIB (IRESSA™) IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) ON A COMPASSIONATE USE PROTOCOL
    Di Emidio, K.
    Barbieri, F.
    Bavieri, M.
    Pifferi, M.
    Marchioni, A.
    Fabbri, L. M.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2004, 15 : 32 - 32
  • [24] Role of gefitinib (G) in heavily pretreated non-small cell lung cancer (NSCLC)
    Tamburini, E.
    Tassinari, D.
    Pasquini, E.
    Papi, M.
    Possenti, C.
    Drudi, F.
    Castellani, C.
    Santelmo, C.
    Carloni, F.
    Ravaioli, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib
    Spreafico, A
    Gregorc, V
    Ludovini, V
    Pistola, L
    Amoroso, M
    Tofanetti, F
    Compagnoni, A
    Aondio, G
    Tonato, M
    Villa, E
    LUNG CANCER, 2005, 49 : S112 - S113
  • [26] Gefitinib and celecoxib in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel, SM
    Shehadeh, NJ
    Ruckdeschel, JC
    Chaplen, RA
    Belzer, K
    Wozniak, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 639S - 639S
  • [27] EGFR mutation and EGFR intron-1 polymorphism predict gefitinib activity in advanced non-small cell lung cancer (NSCLC)
    Franciosi, V.
    Tiseo, M.
    De Palma, G.
    Loprevite, M.
    Chiaramondia, M.
    Rindi, G.
    Naldi, N.
    Bozzetti, C.
    Camisa, R.
    Ardizzoni, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 218 - 218
  • [28] Does KRAS mutation status predicts for chemoresistance in advanced non-small cell lung cancer (NSCLC)?
    Macerelli, M.
    Faivre, L.
    Besse, B.
    Planchard, D.
    Caramella, C.
    Polo, V.
    Pignon, J. P.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S797 - S797
  • [29] PREDICTORS OF GEFITINIB ANTITUMOR ACTIVITY AND SURVIVAL BENEFIT IN EAST ASIAN CHEMONAIVE PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER
    Yang, C.
    Chang, G.
    Tsai, C.
    Kuo, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 107 - 107
  • [30] Management of patients with advanced non-small cell lung cancer: role of gefitinib
    Velcheti, Vamsidhar
    Morgensztern, Daniel
    Govindan, Ramaswamy
    BIOLOGICS-TARGETS & THERAPY, 2010, 4 : 83 - 90
12345